Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Alan P Skarbnik(Novant Health), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Jennifer R. Brown(Dana-Farber Cancer Institute), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Nitin Jain(Parul University), Constantine S. Tam(The Alfred Hospital), John M. Pagel(University of Washington), Kerry A. Rogers(The Ohio State University), Danielle M. Brander(Duke University), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Mazyar Shadman(University of Washington), Toby A. Eyre(Oxford University Hospitals NHS Trust), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Arnon P. Kater(Amsterdam University Medical Centers), Meghan C. Thompson(Memorial Sloan Kettering Cancer Center), Chan Y. Cheah(The University of Western Australia), Clare Sun(National Heart Lung and Blood Institute), Chaitra S. Ujjani(Fred Hutch Cancer Center), Stephen J. Schuster(Hospital of the University of Pennsylvania), John F. Seymour(The Royal Melbourne Hospital), André Goy(Hackensack University Medical Center), Neil E. Kay(Mayo Clinic), Chadi Nabhan(University of Chicago), Susan O’Brien(University of California, Irvine)

Clinical Cancer Research

November 17, 2021

Cited by 21

|Nature Medicine|2013|3k

|New England Journal of Medicine|2013|2.2k

|Molecular Cancer|2023|1.9k

|New England Journal of Medicine|2015|1.9k

|Blood|2018|1.7k

Related Papers